Background: Tobacco price promotions may prompt tobacco trials among youth. We assessed whether receiving price promotions for any tobacco, cigarettes, e-cigarettes and cigars was associated with product use progression.
Methods: The analysis included a nationally representative sample of youth never tobacco users (aged 12-16; n=9405) from wave 4 (2016-2018) of the Population Assessment of Tobacco and Health Study. We assessed past-year receipt of price promotions and use progression (initiation, current use and ever regular use) for any tobacco, cigarettes, e-cigarettes and cigars 1 year later at wave 4.5 (2017-2018). Multivariable logistic regressions were used to examine the associations between receiving price promotions and use progression by product type, controlling for covariates.
Results: At wave 4.5, 9.4% of youth initiated any tobacco (1.8%, 7.8% and 0.9% for cigarettes, e-cigarettes and cigars), and 5.4% received any price promotions (3.8%, 3.1% and 0.9% for cigarettes, e-cigarettes and cigars). Receiving any tobacco price promotions was associated with any tobacco initiation (adjusted OR (AOR)=1.77; 95% CI 1.30 to 2.41), current use (AOR=1.54; 95% CI 1.06 to 2.23) and ever regular use (AOR=1.76; 95% CI 1.04 to 3.10). Receiving e-cigarette price promotions was associated with e-cigarette initiation (AOR=1.78; 95% CI 1.18 to 2.26), current use (AOR=1.88; 95% CI 1.17 to 3.02) and ever regular use (AOR=2.10; 95% CI 1.02 to 4.40). The associations specific to cigarettes and cigars were only found for product initiation.
Discussion: Receiving price promotions for any tobacco and e-cigarettes was respectively associated with the use progression of any tobacco and e-cigarettes. Continuous monitoring of tobacco marketing activities is needed to identify youth-appealing price promotion tactics.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8782922 | PMC |
http://dx.doi.org/10.1136/tobaccocontrol-2021-056667 | DOI Listing |
Prev Med Rep
November 2024
Higher Institute of Public Health, Faculty of Medicine, Saint-Joseph University, Beirut, Lebanon.
Background: Exposure to Ultraviolet radiation (UVR) is a major risk factor for skin cancer. Data about UVR risk knowledge and exposure behaviors in the Lebanese population are scarce.
Aim: To evaluate the association between UVR risks knowledge, attitudes, and behaviors among Lebanese university students in the aim of promoting primary prevention of skin cancer.
BMJ Open
January 2025
Health Economics and Health Technology assessment, School of Health and Wellbeing, University of Glasgow, Glasgow, UK.
Objectives: To identify, measure and value the economic burden of musculoskeletal (MSK) disorders in the Kilimanjaro region, Tanzania.
Design: Community-based cross-sectional survey (undertaken between January and September 2021).
Setting: Hai district, Kilimanjaro, Tanzania.
JMIR Form Res
January 2025
Jim Pickett Consulting, Chicago, IL, United States.
Background: Sexual and gender minority (SGM) adolescents in the United States are disproportionately affected by HIV. Pre-exposure prophylaxis (PrEP) is a highly effective biomedical HIV prevention method, but its awareness and uptake among SGM adolescents are low. There are no adolescent-centered PrEP social marketing campaigns in the United States that have the potential to increase awareness and interest in PrEP.
View Article and Find Full Text PDFInt J Behav Nutr Phys Act
January 2025
Department of Epidemiology and Health Statistics, Xiangya School of Public Health, Central South University, 110 Xiangya Road, Changsha, 410078, Hunan, China.
Background: Low physical activity (LPA) is a leading risk factor for type 2 diabetes mellitus (T2DM). We examine the temporal and spatial trends in the burden of T2DM attributable to LPA at the global, regional, and country scales.
Methods: Data were obtained from the Global Burden of Disease Study 2021.
Curr Top Med Chem
January 2025
College of Biotechnology and Food Science, Tianjin University of Commerce, Tianjin, 300134, China.
Inflammatory Bowel Disease (IBD) is a chronic non-specific disease that affects the gastrointestinal tract, and Intestinal Mucosal Barrier (IMB) damage is closely related to its pathogenesis. The management of IBD often involves repairing the mechanical, chemical, immune, or biological barriers of the intestinal mucosa to alleviate symptoms. Currently, the treatment of IBD patients requires continuous medication or surgical interventions, which can cause irreversible damage to the patient's body over time.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!